Key result
Mitoxantrone achieved combined complete and partial response rates of 37% in patients with relapsed non-Hodgkin's lymphoma and 36% in patients with Hodgkin's disease.
Why the study?
Does mitoxantrone improve response rates in patients with relapsed non-Hodgkin's lymphoma or Hodgkin's disease?
Does mitoxantrone improve response rates in patients with relapsed non-Hodgkin's lymphoma or Hodgkin's disease?
Mitoxantrone demonstrated a 36-37% overall response rate in heavily pretreated patients with relapsed non-Hodgkin's lymphoma or Hodgkin's disease.
No takes yet. Share an insight, caveat, or question.
May merit consideration in relapsed lymphomas; leaves open randomized confirmation of benefit.
Silver et al. (1991) studied Relapsed non-Hodgkin's lymphoma or Hodgkin's disease (n=206). Mitoxantrone was evaluated on Combined complete and partial response rates. Mitoxantrone achieved combined complete and partial response rates of 37% in patients with relapsed non-Hodgkin's lymphoma and 36% in patients with Hodgkin's disease.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: